-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: Features of CDX in vivo drug efficacy test platform
Author:
InnoModels
Release time:
2024-03-11
With the rapid development of the biopharmaceutical industry, there is an increasing demand for drug development and efficacy evaluation. Against this backdrop, InnoModels Biotechnology has revolutionized the drug discovery and development field with its CDX in vivo efficacy testing platform. The platform not only has more than 500 validated tumor cell lines, but also can perform a variety of in vivo efficacy and PK/PD experiments including subcutaneous, in situ and systemic inoculation.
Highly Diverse Tumor Cell Lines
The CDX in vivo efficacy testing platform of InnoModels Biotechnology has over 500 validated tumor cell lines, covering a wide range of cancer types. This means that researchers can select the most appropriate tumor cell lines for drug screening and efficacy assessment according to different research needs. This highly diverse range of tumor cell lines provides a more comprehensive and precise experimental basis for drug development.
comprehensive coverage of in vivo drug efficacy experiments
In addition to a rich variety of tumor cell lines, the CDX platform of InnoModels Biotechnology is also capable of conducting various in vivo efficacy experiments, including subcutaneous, in situ inoculation, and systemic inoculation. These experimental methods can simulate the real action environment of drugs in vivo, so as to more accurately assess the efficacy and safety of drugs. In addition, the platform can be used in combination with PBMC humanized immune system reconstructed mice and CD34+HSC humanized immune system humanized mice, further improving the reliability and accuracy of the experiments.

Highly efficient PK/PD experimental capability
In addition to in vivo efficacy experiments, InnoModels' CDX platform is also equipped with powerful PK/PD (pharmacokinetic/pharmacodynamic) experimental capabilities. By conducting detailed studies on the absorption, distribution, metabolism and excretion of drugs in the body, we can gain a deeper understanding of the drug's mechanism of action and efficacy characteristics. This provides strong support for optimization and improvement in the drug development process.
Innovative Technical Support
InnoModels' CDX platform also relies on its self-developed NIG mice and other advanced technologies. These technologies have higher levels of innate immunity and are more tolerant to specific types of tumor cells such as BAF3 engineered cell lines. This means that when conducting in vivo drug efficacy experiments, they can better mimic the real human environment, thus improving the accuracy and reliability of the experiments.
In conclusion, with its highly diversified tumor cell lines, comprehensive coverage of in vivo efficacy experiments, highly efficient PK/PD experimental capabilities, and innovative technological support, InnoModels' CDX modeling platform has brought about a revolutionary change in the field of drug discovery and efficacy evaluation. The application of this platform is expected to promote the acceleration of the drug development process and the rapid launch of new drugs, and make greater contributions to the cause of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd